Solid Biosciences Inc
SLDB
查看详细走势图
5.900USD
-0.080-1.34%
收盘 12/23, 16:00（美东）报价延迟15分钟
459.51M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-1.34%
5天
+3.33%
1月
+25.53%
6月
+23.17%
今年开始到现在
+47.50%
1年
+41.83%
查看详细走势图
TradingKey Solid Biosciences Inc股票评分
单位: USD 更新时间: 2025-12-22操作建议
Solid Biosciences Inc当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名37/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价15.23。中期看，股价处于平稳状态。近一个月，市场表现很强，技术面和基本面综合得分较高，很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Solid Biosciences Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
14
位分析师
买入
评级
15.231
目标均价
+166.74%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Solid Biosciences Inc亮点
亮点风险
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
利润高增长
公司净利润处于行业前列，最新年度总收入0.00美元
估值低估
公司最新PE估值-2.42，处于3年历史低位
机构减仓
最新机构持股82.26M股，环比减少7.08%
PRFDX持仓
明星投资者PRFDX持仓，最新持仓市值6.48K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.46
Solid Biosciences Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Solid Biosciences Inc简介
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
公司代码SLDB
公司Solid Biosciences Inc
CEOCumbo (Alexander)
网址https://www.solidbio.com/
常见问题
Solid Biosciences Inc(SLDB)的当前股价是多少？
Solid Biosciences Inc(SLDB)的当前股价是 5.900。
Solid Biosciences Inc的股票代码是什么？
Solid Biosciences Inc的股票代码是SLDB。
Solid Biosciences Inc股票的52周最高点是多少？
Solid Biosciences Inc股票的52周最高点是7.370。
Solid Biosciences Inc股票的52周最低点是多少？
Solid Biosciences Inc股票的52周最低点是2.410。
Solid Biosciences Inc的市值是多少？
Solid Biosciences Inc的市值是459.51M。
Solid Biosciences Inc的净利润是多少？
Solid Biosciences Inc的净利润为-124.70M。
现在Solid Biosciences Inc(SLDB)的股票是买入、持有还是卖出？
根据分析师评级，Solid Biosciences Inc(SLDB)的总体评级为买入，目标价格为15.231。
Solid Biosciences Inc(SLDB)股票的每股收益（EPS TTM）是多少
Solid Biosciences Inc(SLDB)股票的每股收益（EPS TTM）是-2.476。
相关品种
